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ABSTRACT 
 
Molecular Analysis Reveals Unique Microbiome in Ileal Pouch During Pouchitis 
Compared to Healthy Pouches in Ulcerative Colitis and Familial Adenomatous Polyposis 
 
Tiffany Wallingford Glavan 
 
In severe cases of ulcerative colitis (UC) unresponsive to current treatment options, 
patients require a complete proctocolectomy, or surgical removal of the colon. Ileal 
pouch anal anastomosis (IPAA) has become the preferred surgical technique for 
patients who require surgery, as this method restores rectal function. This procedure is 
also used to treat colorectal cancers such as adenocarcinoma and familial adenomatous 
polyposis (FAP). The surgery involves an abdominal colectomy with the construction of 
an ileal pouch created from folded tissue recovered from the ileal portion of the small 
intestine. Up to 50% of patients who require IPAA surgery experience an episode of 
pouchitis, a non-specific inflammation of the constructed ileal pouch with unknown 
etiology. Several hypotheses have been proposed regarding the pathogenesis of 
pouchitis. Current theories include bacterial overgrowth due to fecal stasis, microbial 
imbalance (dysbiosis), immune alteration, genetic susceptibility, metaplasia, ischemic 
complications of surgery, a recurrence of UC, or even a novel form of inflammatory 
bowel disease. The efficacy of antibiotics and probiotics in treating pouchitis and 
maintaining remission underscores the importance of gut microbiota in the development 
of this condition. In the study, we aimed to characterize the intestinal bacterial 
communities that inhabit IPAA pouches of both UC and FAP patients, in an effort to 
investigate the hypothesis that bacterial dysbiosis is involved in the pathogenesis of 
pouchitis. Mucosal biopsy and stool samples were analyzed from patients with UC and 
pouchitis (UCP), healthy UC controls (HUC) and healthy pouches with a background of 
FAP (FAP). Samples were examined through analysis of terminal restriction fragment 
length polymorphisms (TRF) and DNA sequencing. The data presented here 
demonstrate that a microbial imbalance exists in pouchitis, as bacterial communities in 
pouchitis differ significantly from healthy UC pouches and pouches constructed for FAP. 
Both methods identified potential groups of organisms that may play a role in the 
development of pouchitis, including decreases in protective Lactobacillus and 
Bacteroides and increases in mucin-degrading Clostridium and Akkermansia. A better 
understanding of the factors driving the pathogenesis of pouchitis will not only benefit 
patients with this disease, but also lead to a better understanding of the complex 
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relationship that exists between the human host and the diverse community of 
organisms that inhabit the gastrointestinal tract.   
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1.1  INTRODUCTION 
Ulcerative colitis (UC) is a chronic but intermittent inflammatory bowel disease 
(IBD) characterized by continuous ulcers, or open sores, in the mucosal layer lining the 
large intestine [1]. This disease has a prevalence of 246 per 100,000 in the United 
States, equating to approximately 700,000 Americans suffering from symptoms including 
abdominal pain and cramping, bloody diarrhea, and fever [2]. The symptoms range in 
severity and can be localized to the rectum or involve the entire colon, but unlike Crohn’s 
disease, UC is restricted to the large intestine [1]. The etiology of this condition is 
unknown, but studies indicate that both genetic and environmental factors are important. 
Hypotheses regarding the origin of UC include an autoimmune response to an antigen, a 
dysfunctional immune response to commensal organisms, or an infection with a 
pathogenic microbe [1].  
Treatment for UC includes anti-inflammatory drugs and immunomodulators, 
which effectively suppress the disease in most cases [1]. Approximately 20-30% of 
patients, however, do not respond effectively to drug therapy and instead require 
surgical intervention [3]. Unlike Crohn’s disease, ulcerative colitis can be cured, in some 
cases, by removal of the large intestines. The restorative proctocolectomy with ileal 
pouch anal anastomosis (IPAA) has become the preferred surgical procedure used to 
treat patients with severe UC [4]. This method involves an abdominal colectomy with the 
creation of a pouch that is connected to the anus. The pouch is constructed from loops 
of folded tissue recovered from the ileal portion of the small intestine. The alternative 
surgical procedure involves the connection of the small intestine directly through the 
abdominal wall. IPAA surgery is favored because the rectal muscular cuff and anal 
sphincter are left intact, eliminating the need for a collection bag.     
Although IPAA surgery has functional advantages over previously used surgical 
techniques, a significant number of patients exhibit post-surgical complications. The 
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most common is pouchitis, a nonspecific inflammatory condition that occurs in the 
reconstructed ileal pouch.  Approximately one-half of all UC patients who receive IPAA 
surgery will develop pouchitis during their lifetime, a syndrome involving watery, frequent 
diarrhea accompanied by urgency, incontinence, abdominal cramping, and fever [5-6]. 
Although the majority of pouchitis patients respond to antibiotics, the condition will 
frequently return and becomes recurrent in approximately10-15% of patients [5, 7].   
Several hypotheses have been proposed regarding the pathogenesis of 
pouchitis. Current theories include the following: bacterial overgrowth due to fecal stasis, 
bacterial dysbiosis (imbalance), immune alteration, genetic susceptibility, metaplasia, 
ischemic complications of surgery, a recurrence of UC, or even a novel form of IBD [8]. 
Multiple lines of evidence point to a pivotal role for bacteria in pouchitis. First of all, 
inflammation of the mucosa has been shown to be localized to areas with the highest 
concentration of bacteria [9]. In addition, sonicated flora from pouchitis patients induces 
activation of ex vivo mononuclear cells while sonicates from healthy patients did not [10]. 
Furthermore, symptoms associated with pouchitis are often effectively treated with 
antibiotics [11-12]. Four week treatment of metronidazole with ciprofloxacin has been 
shown to be highly effective in patients with recurrent or refractory pouchitis [13].  
Metronidazole accumulates in anaerobes and produces toxic free radicals, while 
ciprofloxacin is a broad spectrum antibiotic that inhibits DNA gyrase, halting bacterial 
replication. These two antibiotics have been shown to work best synergistically [7, 14].  
Additional evidence supporting the involvement of intestinal microflora in 
pouchitis is the efficacy demonstrated by probiotic VSL#3 in maintaining remission after 
recovering from an episode of pouchitis [7, 15]. VSL#3, marketed as “The Living Shield”, 
is s mixture of eight different strains of bacteria, including Bifidobacteria, Lactobacillus, 
and Streptococcus. A once daily high dose administration of VSL#3 has been shown to 
be effective in maintaining antibiotic introduced remission in patients experiencing 
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recurrent pouchitis or pouchitis refractory to therapy [7]. Patients treated with VSL#3 are 
shown to have lower levels of mucosal mRNA expression of proinflammatory cytokines 
IL-1β, IL-8, and IFNγ [16]. VSL#3 has also demonstrated efficacy in treating ulcerative 
colitis [17]. Single-strain probiotic Lactobacillus rhamnosus GG has also been tested in 
cases of pouchitis, but effects were limited [18]. 
This clinical evidence has prompted much investigation into the relationship 
between pouchitis and intestinal bacteria. The results of these studies, however, are 
mixed, and no study has been able to identify a single pathogenic organism or toxin 
responsible for pouchitis. Multiple groups have used culture-based techniques that 
indicate a decrease in the ratio of anaerobic to aerobic bacteria in pouchitis [19-21]. 
Several studies cite an increase in sulfate reducing bacteria in the pouches of UC 
patients and implicate the production of hydrogen sulfide gas in the development of 
pouchitis [22-23]. Other studies have implicated increases in Clostridia or Fusobacter 
and decreases in Lactobacilli, Bifidobacteria or Streptococci [24-26]. Yet other studies 
indicate no difference in microbiological communities between inflamed and healthy 
pouches [22, 27-29].  
Part of the reason for the inconsistent findings between studies is the high 
subjectivity in the classification of pouchitis. Prior to 1994, the criteria used in the 
diagnosis of pouchitis varied widely between clinicians. A classification system has since 
been developed in order to objectively quantify the condition of pouchitis, using a 
diagnostic scoring system known as the pouchitis disease activity index (PDAI) [30]. The 
PDAI score is determined using three principal components: symptoms (0-6pts), 
endoscopy (0-6pts), and histology (2-6pts). The clinical section of the PDAI rates 
symptoms such as stool frequency, rectal bleeding, fecal urgency or abdominal 
cramping, and fever. The level of inflammation is described during endoscopy through 
observation of factors such as edema, granularity, and ulceration. The histological 
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section of the score considers levels of polymorphic nuclear leukocyte infiltration and 
ulcerations per low-power field. A combined score greater than seven qualifies as 
pouchitis. The use of the PDAI scoring system has led to more consistent classification 
of pouchitis patients.  
Another probable reason for the discrepancies in findings between studies is the 
variation in the types of control samples used for comparison to pouchitis. It is difficult to 
compare ileal pouch flora from pouchitis patients directly to ileal flora of healthy patients, 
due to inherent challenges in collecting samples from the small intestines. The majority 
of studies compare inflamed UC pouches to healthy UC pouches or to ileostomy. The 
problem with this comparison is that it does not detect differences that may be due to the 
underlying condition of ulcerative colitis, since all samples have a background of the 
disease. In the study presented here, patients who receive IPAA surgery for UC are 
compared to patients who underwent the same surgery for familial adenomatous 
polyposis (FAP). FAP is a heritable condition in which hundreds to thousands of polyps 
form in the mucosal surface lining the intestine. If not treated, these polyps almost 
inevitably transform into malignancies, therefore surgery is employed in FAP cases to 
eliminate the risk of colon cancer.  Patients who undergo IPAA surgery due to familial 
adenomatous polyposis (FAP) are ten times less likely to experience symptoms of 
pouchitis [31-32].  
In addition to subjectivity in classification and variation in the types of samples 
compared, a third reason for inconstant findings within pouch microbiota studies is high 
variability in the experimental techniques (compounded by high intersubject variability). 
Available methodologies for studying gut microbiota have changed dramatically over the 
past twenty years. Original culture based techniques were problematic with gut samples, 
due to the high numbers of anaerobes and the difficulty in growing fastidious organisms 
or those with mutualistic dependence on other species. It is estimated that only about 
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20% of organisms can be cultured from the gut. Molecular techniques for community 
fingerprinting are now more commonly used and are typically based on variability within 
conserved regions of the 16S ribosomal RNA gene. The techniques are similar in that all 
start with PCR using primers for sequences in this gene that are conserved in all 
prokaryotes. The methods differ in how the fragments are separated. Density Gradient 
Gel Electrophoresis (DGGE) uses chemical gradients of urea and formamide to separate 
fragments and temperature gradient gel electrophoresis (TGGE) is based on sequence 
dependent differences in the temperature at which double stranded DNA melts. In 
Terminal Restriction Fragment Length Polymorphism (TRFLP or TRF) one end of each 
PCR-amplified fragment is fluorescently labeled and the fragments are digested with 
restriction enzymes and separated using capillary gel electrophoresis on an automated 
sequence analyzer. TRF data have the advantage of being simply and rapidly produced, 
providing more information than DGGE or TGGE. Data are easily converted into a form 
that can be analyzed using a variety of statistical approaches and databases are 
available for comparison. Ideally, TRF is used for monitoring bacterial community 
structure over time. The resolution of TRF is, however, limited, as fragment sizes overlap 
in most cases, making absolute identification impossible. As more restriction enzymes 
are used, however, more information is available to differentiate species of bacteria. In 
addition to analysis using TRF profiles, PCR amplicons derived from this study were also 
sent for DNA sequencing. Sequences of 16S ribosomal RNA genes provide more power 
to precisely identify the community composition in inflamed pouches versus healthy 
controls.  
Both colonic biopsies and stool samples were obtained from IPAA patients 
enrolled in this study. The concurrent analysis of both mucosal and luminal samples is a 
strength of this study compared to earlier studies that generally assessed only stool 
samples. Analysis of mucosa is important since it has been shown that microorganisms 
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interacting with the mucosa are significantly different than those found in fecal samples, 
and the interaction between the organisms is thought to be integral to the development 
of pouchitis [25, 33]. Only two other pouchitis studies compared mucosal and fecal flora 
[20, 25].  
The aim of this study was to characterize the intestinal bacteria that inhabit IPAA 
pouches of both UC and FAP patients to investigate the hypothesis that an imbalance in 
bacterial populations is involved in the pathogenesis of pouchitis. Mucosa and stool 
samples were analyzed from patients with UC and pouchitis, healthy UC controls and 
FAP controls. Samples were examined using both TRF and DNA sequencing. The data 
presented here demonstrate that bacterial dysbiosis exists in pouchitis and the bacterial 
communities in pouchitis differ significantly from healthy UC pouches as well as from 
pouches constructed for FAP. Both methods identified potential groups of organisms that 
may play a role in the development of pouchitis. A better understanding of the factors 
driving the pathogenesis of pouchitis will not only benefit patients with this disease, but 
also lead to a better understanding of the complex relationships that exist between the 
human host and the diverse community of organisms that inhabit the gastrointestinal 
tract.     
1.2  METHODS 
Inclusion Criteria 
Patients who have received care for a restorative proctocolectomy with IPAA at 
Massachusetts General Hospital were invited to participate in this study. Patients were 
enrolled in this study only if IPAA surgery was performed more than three months prior 
to enrollment. Patients were divided into three cohorts: those with UC and pouchitis 
(UCP); those with UC but no pouchitis (healthy UC pouch, HUC); and those with a 
history of FAP without pouchitis (healthy FAP pouch, FAP). Subjects enrolled as case 
subjects were those experiencing symptoms of at least three episodes of pouchitis in the 
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past year. Pouch inflammation was documented by histological and endoscopic 
investigation and a PDAI score was assigned. PDAI scores greater than seven qualified 
the patient into the pouchitis (UCP) group.  HUC control subjects included patients who 
had never experienced an episode of pouchitis or who had received a PDAI score less 
than seven.  
Exclusion Criteria 
Subjects taking probiotics, non-steroidal anti-inflammatory drugs, and 
immunosuppressants were excluded from the study, as well as any subject who had 
received topical immunosuppressant rectal therapy in the previous two weeks. Subjects 
chronically taking antibiotics were allowed in the study if the antibiotics were 
administered more than three months prior to sample collection and if the patient’s 
symptoms persisted with antibiotic use. Subjects with any clinical evidence of Crohn’s 
disease or any other immunological or hematological illness deemed significant to this 
study were excluded. Nineteen test subjects ultimately enrolled in the study and 
provided informed consent. The Massachusetts General Hospital and California 
Polytechnic State University human subject committees each approved the protocol and 
written consent was obtained from each individual.  
Specimen collection 
The pouch of each patient was examined to determine PDAI score. Each 
enrolled patient underwent a flexible sigmoidscopy performed by one of the study 
physicians. Patients received a bowel preparation one day in advance with phospho-
soda. Both stool and mucosal biopsy specimens were obtained from each test subject. 
One ml stool samples were suctioned into three vials containing 10% glycerol/90% 
sterile water and were immediately placed in dry ice. Biopsies were removed from the 
most inflamed area within the pouch, at least four centimeters from the anus. The 
biopsies were washed in 500 mL of saline and placed into a vial containing 10% 
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glycerol/90% sterile water were immediately placed in dry ice. Both types of samples 
were frozen at -80°C within 30 minutes.   
DNA extractions 
DNA was isolated using MoBio’s Power Soil DNA extraction kit, according to the 
manufacturer’s protocol (MoBio Laboratories, Carlsbad, CA). Triplicate 0.1 g samples 
were used for the extraction of stool samples, while the entire biopsy sample was used 
for the isolation of DNA from tissue samples. The 16S subunit bacterial ribosomal RNA 
gene was amplified from both isolates using the forward primer 8DF (5’-AGA GTT TGT 
TCM TGG CTC AG-3’) and the reverse primer 536-K2R (5’-GTA TTA CCG CGG CTG 
CTG G-3’). The forward primer was fluorescently labeled with a phosphamide dye. 50 µl 
reactions were assembled using 1 µl of undiluted DNA, 5 µl of 10X buffer, 3 µl of 10 mM 
dNTPs, 2 µl of 20mg mL-1 BSA, 7 µl of 25 mM MgCl2, 1 µl of each primer, and 0.3 µl of 5 
UL-1 TaqGold (Applied Biosystems, Foster City, CA). Reaction temperatures and times 
were as follows: 95°C for 10 min followed by 30 cycles of 95°C for 1 min, 60°C for 1 min, 
and 72°C for 2 min, followed by a final extension of 72°C for 10 min. The quality of the 
extractions and PCR reactions were confirmed using gel electrophoresis.  PCR 
triplicates were combined during a PCR cleanup performed using MoBio’s PCR Cleanup 
Kit following the manufacturer’s protocol (MoBio Laboratories, Carlsbad, CA). PCR 
products were quantified using a FLX800 microplate fluorescence reader tuned to the 
labeling dye (Bio-Tek Instruments; Winooski,VT).  
Digestion and Resolution of TRF patterns 
Enzyme digests were independently performed using cleaned-up PCR product 
and the restriction endonucleases HaeIII, HpaII, and AluI (New England Biolabs; 
Beverly, MA). Each 40 µl digest included 75 ng DNA, 1 U enzyme, and 4 µl buffer. 
Samples were digested for 4 h at 37°C and inactivated for 20 min at either 65°C (HpaII 
and AluI) or 80°C (HaeIII). Resulting fragments were ethanol precipitated and 
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resuspended in 20 µl formamide and 0.25 µl CEQ 600 base pair standard. Terminal 
restriction fragments were separated using capillary gel electrophoresis and profiles 
were obtained using a Beckman Coulter CEQ8000X DNA analysis system.  
Terminal restriction fragment lengths (in nucleotides) and relative peak areas 
(relative abundance) were exported from the CEQ8000 into Excel (Microsoft, Seattle, 
WA). The area under each peak was normalized for loading and expressed in parts per 
million to standardize the data for comparison. Peaks with an area less than 10,000 ppm 
(<1.0% of the total) were excluded from the analysis to reduce excess noise. Data from 
three independent restriction digests were performed to provide better resolution (reduce 
incidence of distinct sequences with equivalent TRF lengths) and thus help tentatively 
identify groups when performing database comparisons between fragment lengths and 
in silico restriction enzyme digests of 16S rRNA gene sequences in GenBank (NCBI, 
Bethesda, MD).  
Data analysis 
TRF data sets were transformed by taking the square root of the area under each 
peak to de-emphasize large TRF peaks while still accounting for relative abundance. 
Transformed data were compared using Bray-Curtis similarity, multidimensional scaling, 
and analysis of similarity (Primer, London, UK; Microsoft Excel, Seattle, WA). TRF 
fragments were subjected to ANOSIM analysis to determine the TRF fragments that 
differ most between groups. These fragments were compared to available GenBank 
sequences to tentatively identify potential bacterial populations associated with bacterial 
dysbiosis. The database for TRF matching was created by obtaining all 16S rRNA gene 
sequences from GenBank. These sequences were processed using in silico PCR and 
restriction enzyme digests. Observed TRF peaks were compared to the predicted 
lengths based on the database, allowing for a difference of one base pair between the 
lengths of observed and predicted fragments.  
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Statistics 
Transformed data were compared between groups using Bray-Curtis similarity, 
multidimensional scaling, and analysis of similarity (ANOSIM) (Primer E, Plymouth, UK). 
Bray-Curtis was used to determine overall level of similarity between groups. ANOSIM 
was used to identify the factors that made the groups different. ANOVA was used to 
compare relative abundances of specific TRF elements between groups.  
16S Ribosomal DNA-based DNA Sequencing 
Four fecal samples from each of the UCP and FAP groups were selected and 
pooled for sequencing analysis. Samples were chosen based on greatest intersubject 
similarity, using Bray-Curtis similarity indices. Extracts from selected samples were 
subjected to PCR with the same primers used in TRF, without the fluorescent label. 
Resulting fragments were pooled and sent to the Broad Institute in Cambridge 
Massachusetts for sequencing.  
Samples were cloned into pCR2.1-TOPO vectors and sequenced on an ABI3730 
DNA sequencer. Resulting sequences were trimmed using LUCY, a tool that examines 
raw DNA sequence data for quality assurance [34]. Read pairs from each clone were 
assembled using an alignment-assisted assembly method implemented at the Broad 
Institute. 16S rRNA gene sequences obtained from Greengenes provided the alignment 
template used as a reference sequence for the read pairs [35]. The reference sequence 
with the greatest number of k-mers matching with the aggregate k-mer set of both 
forward and reverse reads was selected. The forward and reverse reads were aligned to 
the core reference sequence using basic local alignment search tool (NCBI, Bethesda, 
MD) [36]. Aligned forward and reverse reads were then assembled based on base 
quality scores. High quality reads longer than 1100 nucleotides were used for 
classification. Sequences were classified according to comparisons with the Ribosomal 
Database Project sequence collection [37-38].  
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1.3  RESULTS 
Patient Characteristics 
Nineteen patients were enrolled in the study. The samples were divided into 
groups based on the reason for IPAA surgery (ulcerative colitis vs. familial adenomatous 
polyposis) and the PDAI score (healthy pouch vs. pouchitis) (Table 1). Twelve patients 
received surgery for ulcerative colitis, and of these 9 had pouchitis (UCP) and 3 had 
healthy pouches. Seven patients were enrolled that received IPAA surgery for familial 
adenomatous polyposis. There were no significant differences between patient 
demographics (age and gender) or disease characteristics (duration of ulcerative colitis 
and pouch). PDAI scores were significantly higher in the pouchitis group, and each 
biopsy in this group were shown to display histologic evidence of active pouchitis as part 
of the PDAI score (defined by presence of polymorphonuclear infiltrates and 
ulcerations). Several patients enrolled in the UCP group were receiving chronic antibiotic 
therapy. Two patients were currently taking antibiotics, one for eight years and one for 
one year, while still having episodes of pouchitis. Three other patients had received 
short courses of antibiotics during the past year, but not during the three month time 
span prior to enrolling in the study.  
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Terminal Restriction Fragment Analysis 
The total number of peaks provides a measure of overall community diversity. 
There were significant differences in the total number of TRF peaks in the mucosal 
biospsies compared to stool (average total peaks, mucosa=64.8, feces=41.3, p<0.001 ). 
(Figure 1). Fecal and mucosal microbial fingerprints were significantly more similar within 
samples from a single subject compared to between subjects (p=0.027). Compared to 
stool samples, mucosal samples taken as a whole revealed significantly greater 
intersubject percentage similarity (p<0.001). The total number of fecal TRF peaks, a 
marker of overall diversity, was lower in pouchitis compared to stool from healthy 
subjects without proctocolectomy (42.3 in UCP, 64.0 in normal stool, p<0.001). TRFs 
used for this analysis were collected from healthy seniors at California Polytechnic State 
University as part of an independent study. However, HUC and FAP groups also showed 
significantly lower microbial diversity in the stool samples compared to healthy subjects 
without proctocolectomy (HUC=35.3, p<0.05; FAP=41.4, p<0.005). 
 
Figure 1. Representative TRF profiles. These two patterns were generated from the stool and 
mucosa of a single patient. The mucosa had a higher degree of community diversity, based on 
the total number of peaks.  
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Overall, there was a higher degree of similarity within TRF profiles from the FAP 
group (37.78%) compared to the UCP group, where microbial profiles were more 
variable overall (20.11%). TRF profiles were significantly different between UCP and 
FAP groups when evaluating mucosal and stool separately, or when combined (p<0.05, 
Figure 2). Profiles were also distinct between UC patients with and without pouchitis 
(p<0.05). No significant differences were observed in patients taking antibiotic therapy.  
The analysis of similarity (ANOSIM) analysis from the three different restriction 
digests were compared to find sets of peaks that were most different between groups in 
each digest. This analysis revealed a set of TRFs matching Lactobacillus and 
Streptococcus (Hae 264-5, Hpa 97-9, Alu 76,532) were present at higher relative 
abundance in both mucosal and fecal samples from FAP patients compared to UCP 
(ratio 5:1 in mucosa, 3:1 in stool). A second set of TRF peaks (Hae 272-4, Hpa 222-3, 
Alu 440) matching Clostridium, Eubacterium and Roseburia genera were present at five 
time the relative abundance in stool from UCP patients compared to FAP patients. Fecal 
samples from HUC pouches also had fewer peaks matching Clostridium, Eubacterium 
and Roseburia compared to UCP (ratio 1:15). Profiles from healthy UC pouches had 
fewer Escherichia, Streptococcus, and various sulfur-oxidizing bacteria (Hpa 496, Hae 
205, Alu 74) at a ratio of 1:2 compared to UCP. Mucosal samples from healthy UC 
pouches also showed less Escherichia, Streptococcus, and various sulfur-oxidizing 
bacteria compared to UCP (ratio 1:2). There were no groups that were increased in 
healthy UC pouches that were statistically significant.  
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Figure 2. Multi-dimensional scaling (MDS) analysis. This analysis is used to compare TRF 
profiles between groups. Each symbol represents the profile of one subject and the distance 
between symbols is representative of overall similarity. Significant differences in microbial 
communities were observed between each experimental group.  
 
DNA Sequencing 
Pooled fragments from the UCP and FAP group were sent for cloning and 
sequencing at the Broad Institute.  For each of the samples, 2304 clones were 
processed in total. In the UCP pooled sample, 712 sequences were identified at the 
genus level, and for the FAP samples, 1015 were identified. The groups were first 
compared at the phylum level. These data showed increased Firmicutes and 
Verrucomicrobia in the UCP group and more Bacteroidetes in the FAP group 
(p<0.001)(Table 2). Sequences between groups were also compared at the genus level. 
Table 3 shows the classification of the sequences that were different between 
experimental groups. Like the TRF data, the sequencing data revealed more Clostridia, 
namely Roseburia in the UCP group and more Escherichia in the FAP group.  
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1.4  Conclusions/Discussion  
The precise role of intestinal bacteria in the pathogenesis of pouchitis remains 
unclear. This investigation, however, has revealed the existence of distinct pouch 
environments in patients who have pouchitis and those with healthy pouches in UC and 
FAP, using TRF and DNA sequencing techniques based on sequence variability in the 
gene for 16S rRNA. The pouch microbial environment, including both mucosal and 
luminal communities, is significantly altered in patients with UC-associated pouchitis 
compared to patients who received IPAA surgery in the setting of FAP. These findings 
demonstrate that bacterial dysbiosis exists in pouchitis and thus underscore the 
importance of the relationship between microbiota colonizing the gastrointestinal tract 
and the health of the host. This study was limited by the small number of healthy 
ulcerative colitis patients enrolled and the necessity of pooling fragments prior to DNA 
sequencing.  
Multiple studies have indicated reductions in community diversity in pouchitis [27, 
29], yet other studies demonstrate no change in diversity [39]. In TRF, diversity is 
represented by total number of peaks. The data collected here indicates that there is 
less community diversity in stool samples after IPAA surgery, indicated by fewer overall 
peaks in stool samples from all enrolled patients compared to stool from healthy subjects 
with intact colons. The finding is expected based on the fact that the colon supports a 
much greater bacterial load [40].  Between different experimental groups, however, there 
were not significant differences in total numbers of peaks between each of the three 
groups. The profiles of mucosal biopsies was shown to harbor greater numbers of total 
peaks than the fecal samples, providing supporting evidence for the idea that the 
bacteria found in stool comprise a subset of bacteria found in at the mucosal surface [33] 
(Figure 2).  
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The bacterial community profiles were shown to be significantly different between 
all three experimental groups. This finding suggests that pouchitis is related to 
underlying factors in ulcerative colitis, since the communities found in healthy UC 
pouches was different from healthy FAP pouches. Although symptoms of UC are 
localized to the large intestine, underlying genetic and immune alterations (i.e. NOD2 
polymorphisms or increased cytokine production) could lead to a similar pathology in the 
small intestines post-surgery. This finding is supported by clinical evidence that UC 
pouches are known to be 10X more susceptible to pouchitis than FAP pouches [32].   
Both TRF and sequencing data indicate decreased abundance of protective 
Lactobacillus and Bacteroides in diseased pouches. Both species have well-
demonstrated protective effects for the host. Lactobacillus is a known probiotic organism 
that protects the gut through competitive inhibition of other colonizing microbes. Certain 
species of Lactobacillus have been shown to reduce inflammation in the mouse model of 
inflammatory bowel syndrome, likely by modulating cytokine function. Lactobacillus have 
been shown to increase occludin and claudin production, upregulating tight junction 
formation and helping to maintain epithelial barrier function in the host. Several other 
studies have indicated decreased Lactobacillus in pouchitis [24, 26]. Bacteroidetes, 
specifically genus Bacteroides, typically comprise a large portion of the gastrointestinal 
tract. These mutualistic bacteria also provide competitive inhibition of pathogenic 
species, likely gaining a competitive advantage through the ability to process complex 
polysaccharides. Studies investigating the effects of probiotics on microbial flora report 
increases in Bacteroides after probiotic therapy [41], and this effect may help explain the 
efficacy demonstrated by probiotic therapy in pouchitis. In general, the importance of 
protective species is underscored by the efficacy of probiotic species in maintaining 
remission in pouchitis.  
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Both TRF and sequencing data indicate increased abundance of Phylum 
Firmicutes in diseased pouches, including genus Clostridium and Roseburia. Clostridia 
are resistant spore-forming anaerobes and multiple members of this class are known 
human pathogens. Clostridium difficile is a common opportunistic pathogen that is 
known to increase in abundance after antibiotic treatment. C.difficile infections are 
common in pouchitis, with or without antibiotic treatment [42]. Several species of 
Clostridium are mucolytic and capable of breaking down the protective mucus layer in 
the host’s intestinal lumen, potentially leaving the underlying epithelium more prone to 
invasion. Mucins provide an important energy source for bacteria as well as important 
barrier for the human host. In a healthy host, there exists a balance between the 
production of mucus by goblet cells and the breakdown of mucins by resident bacteria. 
An overabundance of Clostridium could disrupt this balance, due to enhanced 
glycosidase activity. Several other studies have demonstrated increases in Clostridia in 
pouchitis, including Clostridium perfringens [11, 24]. Members of genus Roseburia were 
also increased in diseased pouches. Roseburia are common flagellated butyrate 
producing bacteria. Bacterial flagellin has been shown to be a dominant antigen in 
Crohn’s disease and, furthermore, serum IgG from patients with CD and mice with colitis 
both reacted specifically to flagellin from Roseburia [43]. Another group that was shown 
to be increased in diseased pouches was Akkermansia in Phylum Verrucomicrobia. This 
genus, like Clostridia, is known for mucin degradation. The loss of the protective mucus 
layer allows for direct contact between the intestinal epithelium and commensal 
organisms and may perpetuate inflammation.  
These data, along with many previous studies, fail to pinpoint one specific group 
of bacteria associated with pouchitis, and therefore do not support the hypothesis that a 
single pathogenic organism leads to inflammation in pouchitis. Evidence in a shift of 
predominant microbial communities, however, was apparent. These findings provide 
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support for the hypothesis that pouchitis involves alterations in the homeostasis of 
commensal organisms. Increased abundance of colitogenic bacterial species, such as 
Clostridia and Akkermansia identified in this study, may initiate inflammation by 
disrupting barrier function or destroying the mucosal surface of the host gastrointestinal 
tract.  
It is, however, difficult to separate cause from consequence. Changes in 
microbial structure could initiate inflammation, but changes in immune function could 
drive changes in microbial communities. There is mounting evidence that links immune 
alterations to pouchitis, and it is hypothesized that a loss of tolerance to commensal 
organisms leads to inflammation. Ferrante et al retrospectively investigated serum 
antibody production and pattern recognition receptor polymorphisms in a large cohort of 
IPAA patients and found associations between pouchitis and outer-membrane porin 
antibodies and toll-like receptor 1 polymorphisms, implying immune dysfunction [44]. 
Another study demonstrated increased proliferation of immature plasma cells near ulcers 
and inflamed mucosa of pouchitis, suggesting an immune defect in B cell development 
[45]. Increases have been demonstrated in levels of activated mucosal CD4+ cells and 
multiple proinflammatory cytokines, including IFNγ, IL-1β, IL-6, IL-8, and TNFα [46-47].  
High proinflammatory cytokine production promotes inflammation and can lead to 
intestinal epithelial destruction and crypt hyperplasia. Genetic susceptibility loci have 
also been identified that likely contribute to immune dysfunction. A recent study indicates 
that nucleotide oligomerization domain-2 (NOD2) mutations are found at higher 
frequencies in patients with severe pouchitis [48].  
Although it is difficult to separate changes in community makeup and immune 
function in terms of cause and consequence, the importance of the relationship between 
commensal microorganisms and the human host are becoming increasingly clear. Host-
microbe relationships in the gut are the focus of a rapidly growing field of research aimed 
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at understanding how the two interact. Much advancement has been made in 
understanding the role of bacteria in human health. Germ-free mice were the first to 
demonstrate the critical role of bacteria in the development and maturation of the 
immune system, as mice raised in a sterile environment have altered development of 
both gut mucosal and peripheral immune systems, with a lack of expansion of CD4+ T-
cells and a lack of lymphoid structure [49]. Stimulation by bacterial products is necessary 
and sufficient to initiate the maturation process [50].  
In addition to being instrumental in the initial development of the immune system, 
bacteria also help maintain the health of the adult host. Some species of bacteria 
actively stimulate the host to produce anti-microbial peptides and proteins involved in 
tight junction formation, contributing to the maintenance of host epithelial integrity [40]. It 
is well established that bacteria help us digest complex polysaccharides, but only 
recently has it been appreciated that bacteria play a role in how we extract nutrients from 
food and in the uptake of lipids and dietary fiber. The composition of the gut microflora 
has recently been implicated in metabolic disorders such as obesity and diabetes  [40]. 
As more and more data are compiled describing the composition of human intestinal 
microflora, enterotypes, or robust clusters of certain species, are emerging. Certain 
species drive the different enterotypes, based more on microbial functions (i.e. 
metabolism) than host factors (i.e. age or gender) [51]. It is hypothesized that persons 
with different microbial enterotypes respond differently to diet and drug intake.  
Collectively, research on host-microbe interactions in the gut has demonstrated 
that there is a complex interplay in mucosal immunology between three systems that 
determine gastrointestinal health: host genetics, bacterial community structure, and 
immune function. Each system can influence the other systems and the wrong 
combinations of aberrant factors lead to mucosal pathogenesis. The pathogenesis of 
pouchitis, like gut health in general, is likely to be multi-factorial, involving overlapping 
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factors and creating a spectrum of disorders rather than a single disease. Much work is 
left to be done to uncover the complex host-microbe relationships and interactions 
between microbes and the host. Future studies should aim to concurrently study 
microbiota while also investigating immune function through cytokine and antibody 
production, or attempt to link pouchitis with genetic polymorphisms in large patient 
cohorts. Knowledge gained from future research efforts in this area will have wide 
applications to improving human health and well-being, not only including patients 
suffering from pouchitis after IPAA surgery. The complexity and diversity of life in our 
intestines and the relationship between the host and resident bacterial community pose 
a significant challenge to researchers, but the knowledge gained from these studies has 
the potential to dramatically increase our understanding of human health.  
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